Surya Pharmaceutical (Delisted) financials and balance sheet

BSE: 532516

Last traded ₹0.15 on 14 Sep 2015

Delisted on 11 May 2018.

6 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Surya Pharmaceutical annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
Peak revenue ₹1,650 Cr, year to Mar 2012A loss in 2 of the 6 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2013

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue60
  2. Operating expenses−217
  3. Operating profit−157
  4. Depreciation−62
  5. Other income−18
  6. Finance costs−204
  7. Profit before tax−441
  8. Tax+144
  9. Net profit−315

Profit and loss

Standalone, ₹ crore, years to March.Surya Pharmaceutical quarterly results

₹ croreMar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013
Revenue from operations4977231,1301,6081,65060
4126059671,3521,472217
Materials and goods bought3755498871,2361,46492
Employee costs8172842––
Other expenses29395274––
Operating profit before depreciation84118163257178−157
Operating margin17.0%16.3%14.4%16.0%10.8%−260.2%
Materials, % of revenue75.4%75.9%78.5%76.9%––
Employee costs, % of revenue1.7%2.4%2.5%2.6%––
Other expenses, % of revenue5.9%5.4%4.6%4.6%––
Depreciation and amortisation101721263562
Operating profit after depreciation74101142230144−219
Other income1510––−18
Finance costs20416299181204
Profit before tax556490131−38−441
Tax981526–−144
Net profit475675105−38−315
Net margin9.4%7.8%6.6%6.5%−2.3%−521.3%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the years to Mar 2012 and Mar 2013 they do not, so they are left blank.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013
––––––
As stated that year₹34.81–––––
––––––
Market cap at the year end (₹ crore)123–––––
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from.

Ratios

Standalone, years to March.

RatioMar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013
Revenue growth–45.6%56.3%42.3%2.6%−96.3%
Operating profit growth–39.4%38.8%57.2%−30.5%–
Net profit growth–20.5%32.8%40.2%––
Interest cover3.72.52.32.30.8–
Interest cover is left blank for the year to Mar 2013: operating profit after depreciation is a loss, and a loss covers no interest bill.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2013.

Measure5 years3 years
Revenue growth, yearly rate−34.4%−62.3%
Operating margin, average−40.5%−77.8%
Net margin, average−100.5%−172.4%
Interest cover, average2.01.6

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013
Effective tax ratePublished threshold 17.16 per cent15.4012.4316.9919.93––
A threshold marked as ours has no published figure; it is the line we read the check against.